About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline
Nanobiotix announces positive first results for novel NBTXR3 in rectal cancer study at ASCO-GI 2021
15 January 2021
Nanobiotix announces first patient injected with NBTXR3 in esophageal cancer
28 January 2021
Nanobiotix subsidiary Curadigm secures new collaboration agreement with Sanofi focused on gene therapy pipeline
Published by
Julie Ficheux
on
25 January 2021
No translations available for this page
